10-Q Filing

AIM IMMUNOTECH INC. CIK: 946644 Q2 2023

Filing Information

Form Type	10-Q
Accession Number	`0001493152-23-028610`
Period End Date	20230630
Filing Date	20230814
Fiscal Year	2023
Fiscal Period	Q2
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 57 Income Statement 72 Cash Flow Statement 65 Stockholders Equity 29

Balance Sheet 57 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$21.04M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$27.05M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$7.36M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$7.14M	USD	Point-in-time
Funds receivable from New Jersey net operating loss	`AccountsReceivableNetCurrent`	$33.00K	USD	Point-in-time
Funds receivable from New Jersey net operating loss	`AccountsReceivableNetCurrent`	$1.68M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$455.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$438.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$36.32M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$28.87M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$195.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$145.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$781.00K	USD	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$829.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsNet`	$1.94M	USD	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsNet`	$1.97M	USD	Point-in-time
Patent and trademark rights, net	`FiniteLivedIntangibleAssetsNet`	$2.04M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	48.42M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.20M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	48.08M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.78M	USD	Point-in-time
Total assets	`Assets`	$33.62M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	48.42M	shares	Point-in-time
Total assets	`Assets`	$40.49M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	48.08M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.15M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$377.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$528.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$806.00K	USD	Point-in-time
Current portion of operating lease liability	`OperatingLeaseLiabilityCurrent`	$178.00K	USD	Point-in-time
Current portion of operating lease liability	`OperatingLeaseLiabilityCurrent`	$206.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.36M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.88M	USD	Point-in-time
Operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$597.00K	USD	Point-in-time
Operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$659.00K	USD	Point-in-time
Commitments and contingencies (Notes 12 and 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Notes 12 and 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series B Convertible Preferred Stock, stated value $1,000 per share, 690 and 696 issued and outstanding, respectively	`PreferredStockValue`	$696.00K	USD	Point-in-time
Series B Convertible Preferred Stock, stated value $1,000 per share, 690 and 696 issued and outstanding, respectively	`PreferredStockValue`	$690.00K	USD	Point-in-time
Common Stock, par value $0.001 per share, authorized 350,000,000 shares; 48,419,491 and 48,084,287, issued and outstanding, respectively	`CommonStockValue`	$48.00K	USD	Point-in-time
Common Stock, par value $0.001 per share, authorized 350,000,000 shares; 48,419,491 and 48,084,287, issued and outstanding, respectively	`CommonStockValue`	$48.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$418.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$418.51M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-380.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-389.12M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$30.14M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$56.88M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$48.78M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$38.47M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$34.99M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$53.30M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$33.62M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$40.49M	USD	Point-in-time

Income Statement 72 line items

Line Item	Tag	Value	Unit	Period
Clinical treatment programs - US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$64.00K	USD	2 Qtrs
Clinical treatment programs - US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$42.00K	USD	1 Quarter
Clinical treatment programs - US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$30.00K	USD	1 Quarter
Clinical treatment programs - US	`RevenueFromContractWithCustomerExcludingAssessedTax`	$91.00K	USD	2 Qtrs
Total Revenues	`Revenues`	$42.00K	USD	1 Quarter
Total Revenues	`Revenues`	$30.00K	USD	1 Quarter
Total Revenues	`Revenues`	$91.00K	USD	2 Qtrs
Total Revenues	`Revenues`	$64.00K	USD	2 Qtrs
Production costs	`ManufacturingCosts`	-	USD	2 Qtrs
Production costs	`ManufacturingCosts`	-	USD	1 Quarter
Production costs	`ManufacturingCosts`	$69.00K	USD	1 Quarter
Production costs	`ManufacturingCosts`	$147.00K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.95M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.51M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.48M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.00M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$4.25M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.55M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.18M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.84M	USD	2 Qtrs
Total Costs and Expenses	`CostsAndExpenses`	$7.91M	USD	2 Qtrs
Total Costs and Expenses	`CostsAndExpenses`	$5.50M	USD	1 Quarter
Total Costs and Expenses	`CostsAndExpenses`	$9.85M	USD	2 Qtrs
Total Costs and Expenses	`CostsAndExpenses`	$4.72M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-7.85M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-9.76M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-4.70M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-5.46M	USD	1 Quarter
Gain (Loss) on investments	`GainLossOnInvestments`	$-94.00K	USD	1 Quarter
Gain (Loss) on investments	`GainLossOnInvestments`	$-470.00K	USD	1 Quarter
Gain (Loss) on investments	`GainLossOnInvestments`	$-1.40M	USD	2 Qtrs
Gain (Loss) on investments	`GainLossOnInvestments`	$109.00K	USD	2 Qtrs
Interest and other income	`OtherNonoperatingIncomeExpense`	$517.00K	USD	2 Qtrs
Interest and other income	`OtherNonoperatingIncomeExpense`	$318.00K	USD	1 Quarter
Interest and other income	`OtherNonoperatingIncomeExpense`	$79.00K	USD	1 Quarter
Interest and other income	`OtherNonoperatingIncomeExpense`	$124.00K	USD	2 Qtrs
Interest expense and other finance costs	`InterestExpense`	-	USD	2 Qtrs
Interest expense and other finance costs	`InterestExpense`	-	USD	1 Quarter
Interest expense and other finance costs	`InterestExpense`	-	USD	2 Qtrs
Interest expense and other finance costs	`InterestExpense`	-	USD	1 Quarter
(Loss) on sale of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	1 Quarter
(Loss) on sale of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	1 Quarter
(Loss) on sale of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	2 Qtrs
(Loss) on sale of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	$-23.00K	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	$-3.00K	USD	1 Quarter
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	$-34.00K	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	-	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Gain from sale of Income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-232.00K	USD	1 Quarter
Gain from sale of Income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-422.00K	USD	2 Qtrs
Gain from sale of Income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-582.00K	USD	2 Qtrs
Gain from sale of Income tax operating losses	`GainFromSaleOfIncomeTaxOperatingLoss`	$-328.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-8.67M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-4.85M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-4.91M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-8.57M	USD	2 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.10	USD	1 Quarter
Basic loss per share	`EarningsPerShareBasic`	$-0.18	USD	2 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.18	USD	2 Qtrs
Basic loss per share	`EarningsPerShareBasic`	$-0.10	USD	1 Quarter
Diluted loss per share	`EarningsPerShareDiluted`	$-0.18	USD	2 Qtrs
Diluted loss per share	`EarningsPerShareDiluted`	$-0.18	USD	2 Qtrs
Diluted loss per share	`EarningsPerShareDiluted`	$-0.10	USD	1 Quarter
Diluted loss per share	`EarningsPerShareDiluted`	$-0.10	USD	1 Quarter
Weighted average shares outstanding basic	`WeightedAverageNumberOfSharesIssuedBasic`	48.41M	shares	1 Quarter
Weighted average shares outstanding basic	`WeightedAverageNumberOfSharesIssuedBasic`	48.01M	shares	2 Qtrs
Weighted average shares outstanding basic	`WeightedAverageNumberOfSharesIssuedBasic`	48.41M	shares	2 Qtrs
Weighted average shares outstanding basic	`WeightedAverageNumberOfSharesIssuedBasic`	48.03M	shares	1 Quarter
Weighted average shares outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.01M	shares	2 Qtrs
Weighted average shares outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.41M	shares	1 Quarter
Weighted average shares outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.41M	shares	2 Qtrs
Weighted average shares outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	48.03M	shares	1 Quarter

Cash Flow Statement 65 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-8.67M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-4.85M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.91M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.57M	USD	2 Qtrs
Depreciation of property and equipment	`Depreciation`	$20.00K	USD	2 Qtrs
Depreciation of property and equipment	`Depreciation`	$21.00K	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	$-3.00K	USD	1 Quarter
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	$-34.00K	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	-	USD	2 Qtrs
Redeemable warrants valuation adjustment	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$38.00K	USD	2 Qtrs
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$218.00K	USD	Annual
Amortization of patent, trademark rights	`AmortizationOfIntangibleAssets`	$106.00K	USD	2 Qtrs
Changes in ROU assets	`IncreaseDecreaseinRightofUseAssets`	$48.00K	USD	2 Qtrs
Changes in ROU assets	`IncreaseDecreaseinRightofUseAssets`	$-740.00K	USD	2 Qtrs
Gain from sale of income tax operating losses	`LossGainFromSaleOfIncomeTaxOperatingLosses`	$582.00K	USD	2 Qtrs
Gain from sale of income tax operating losses	`LossGainFromSaleOfIncomeTaxOperatingLosses`	$422.00K	USD	2 Qtrs
Equity-based compensation	`ShareBasedCompensation`	$517.00K	USD	2 Qtrs
Equity-based compensation	`ShareBasedCompensation`	$132.00K	USD	2 Qtrs
(Loss) on sale of marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$109.00K	USD	2 Qtrs
(Loss) on sale of marketable securities	`MarketableSecuritiesUnrealizedGainLoss`	$-1.40M	USD	2 Qtrs
Funds Receivable from New Jersey net operating loss	`IncreaseDecreaseInOtherReceivables`	$-1.68M	USD	2 Qtrs
Funds Receivable from New Jersey net operating loss	`IncreaseDecreaseInOtherReceivables`	$-1.64M	USD	2 Qtrs
Prepaid expenses and other current assets and other non-current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-17.00K	USD	2 Qtrs
Prepaid expenses and other current assets and other non-current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$69.00K	USD	2 Qtrs
Lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$740.00K	USD	2 Qtrs
Lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$-34.00K	USD	2 Qtrs
Other Assets	`IncreaseDecreaseInOtherOperatingAssets`	$39.00K	USD	2 Qtrs
Other Assets	`IncreaseDecreaseInOtherOperatingAssets`	$73.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.77M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$514.00K	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-278.00K	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$64.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-5.07M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-5.84M	USD	2 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$598.00K	USD	2 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$8.71M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$1.26M	USD	2 Qtrs
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$712.00K	USD	2 Qtrs
Proceeds from sale of property and equipment	`ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment`	-	USD	2 Qtrs
Proceeds from sale of property and equipment	`ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment`	$35.00K	USD	2 Qtrs
Purchase of patent and trademark rights	`ProceedsFromPaymentsToAcquireIntangibleAssets`	$203.00K	USD	2 Qtrs
Purchase of patent and trademark rights	`ProceedsFromPaymentsToAcquireIntangibleAssets`	$76.00K	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-282.00K	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$7.38M	USD	2 Qtrs
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	$55.00K	USD	2 Qtrs
Proceeds from sale of stock, net of issuance costs	`ProceedsFromIssuanceOrSaleOfEquity`	$105.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$55.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$105.00K	USD	2 Qtrs
Net (decrease) increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.36M	USD	2 Qtrs
Net (decrease) increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-6.01M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$27.05M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$32.09M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$21.04M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$34.45M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$27.05M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$32.09M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$21.04M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$34.45M	USD	Point-in-time
Operating lease-Right of Use Assets	`OperatingLeaserightOfUseAssets`	$761.00K	USD	2 Qtrs
Operating lease-Right of Use Assets	`OperatingLeaserightOfUseAssets`	$-48.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`UnrealizedGainLossOnMarketableSecurities`	$-225.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`UnrealizedGainLossOnMarketableSecurities`	$196.00K	USD	2 Qtrs
Conversion of Series B preferred	`ConversionOfSeriesBPreferred`	$2.00K	USD	2 Qtrs
Conversion of Series B preferred	`ConversionOfSeriesBPreferred`	$6.00K	USD	2 Qtrs

Stockholders Equity 29 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$30.14M	USD	Point-in-time
Balance	`StockholdersEquity`	$56.88M	USD	Point-in-time
Balance	`StockholdersEquity`	$48.78M	USD	Point-in-time
Balance	`StockholdersEquity`	$38.47M	USD	Point-in-time
Balance	`StockholdersEquity`	$34.99M	USD	Point-in-time
Balance	`StockholdersEquity`	$53.30M	USD	Point-in-time
Common stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$5.00K	USD	1 Quarter
Common stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Common stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$100.00K	USD	1 Quarter
Common stock issuance, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$55.00K	USD	1 Quarter
Common stock issuance, net of costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	11,937.00	shares	2 Qtrs
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$275.00K	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$50.00K	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$242.00K	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$82.00K	USD	1 Quarter
Series B preferred shares converted to common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	1 Quarter
Series B preferred shares converted to common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	1 Quarter
Series B preferred shares converted to common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	1 Quarter
Series B preferred shares converted to common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	1 Quarter
Net Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.66M	USD	1 Quarter
Net Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-4.85M	USD	1 Quarter
Net Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.82M	USD	1 Quarter
Net Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-4.91M	USD	1 Quarter
Balance	`StockholdersEquity`	$30.14M	USD	Point-in-time
Balance	`StockholdersEquity`	$56.88M	USD	Point-in-time
Balance	`StockholdersEquity`	$48.78M	USD	Point-in-time
Balance	`StockholdersEquity`	$38.47M	USD	Point-in-time
Balance	`StockholdersEquity`	$34.99M	USD	Point-in-time
Balance	`StockholdersEquity`	$53.30M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.